Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

1. Introduction: An Overview of the anatomy and physiology of the lung2. Major Challenges in the Lung Cancer Therapy : Distant Metastasis and Drug Resistance3. Active Targeting Systems (Ligands) / Receptor overexpressed on lung cancer4. Polymeric nanoparticles based drug delivery for lung cancer5. Solid lipid nanoparticles based drug delivery for lung cancer6. Liposomes and niosomes based drug delivery for lung cancer7. Dendrimers based drug delivery for lung cancer8. Micelles based drug delivery for lung cancer9. Nanoemulsions based drug delivery for lung cancer10. Nanomedicine-based inhalation treatments for lung cancer11. Towards development of novel diagnostic nano-imaging platform for lung cancer12. Hydrogel based drug delivery for lung cancer13. Quantum dots based drug delivery for lung cancer